Biotech Values

[north40000]

XXII and survey:

http://ih.advfn.com/p.php?pid=nmona&article=72812536

"51% of participants who smoked 22nd Century’s Very Low Nicotine cigarettes predicted that they would quit within one year

22nd Century Group, Inc. (NYSE MKT: XXII), a leader in tobacco harm reduction, announced today that Addiction Journal published online a new report investigating smokers’ cost sensitivity for Very Low Nicotine cigarettes. Led by Dr. Eric C. Donny of the University of Pittsburg Cancer Institute, the new publication found that, compared to conventional cigarettes, 22nd Century’s Very Low Nicotine cigarettes reduced the number of cigarettes that the participants estimated they would smoke at every price range tested. This Phase III study included 839 participants who, over a 6-week period, first smoked their own brand and then were assigned to smoke one of five different nicotine content cigarettes. The researchers exclusively employed 22nd Century’s SPECTRUM® brand cigarettes for their study. SPECTRUM® research cigarettes are provided through the National Institute on Drug Abuse, which is part of the National Institutes of Health...[more]"

We entered with several 1000s at $0.88 in July 2016.